Clinical Trial Update: A Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer. [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for MRG002 in HER2-positive/HER2-low locally advanced or metastatic gastric/gastroesophageal junction cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• MRG002

Snippet

Sponsor: Shanghai Miracogen Inc. | Conditions: Locally Advanced Gastric Cancer, Metastatic HER2 Positive Gastroesophageal Junction Cancer | Phase 2 | Status: UNKNOWN